Objective:　This　clinical　study　was　designed　to　evaluate　the　efficacy　and　safety　of　this　therapy　in　the　treatment　of　respiratory　and　urinary　infections　caused　by　ceftriaxone-resistant　bacteria　in　comparison　with　the　effect　of　cefoperazone/sulbactam　on　cefoperazone-resistant　bacteria.　Methods:　A　total　of　285　patients　aged　from　18　to　65　years　old,　with　a　respiratory　or　urinary　tract　bacterial　infection,　were　enrolled　into　this　multicentre,　open-label,　controlled　clinical　study,　and　bacteria　that　were　either　ceftriaxone-resistant　or　cefoperazone-resistant　were　isolated　from　the　patients,　whose　condition　had　not　improved　after　three　days　of　treatment　with　ceftriaxone　or　cefoperazone.　To　be　selected　for　the　study,　bacterial　cultures　obtained　from　the　patients　had　to　be　positive　before　enrolment,　and　all　of　the　isolates　were　required　to　be　beta-lactamase-positive.　Of　these　patients,　253　completed　the　trial,　and　263　were　enrolled　into　the　intention-to-treat　(ITT)　analysis.　All　of　the　285　patients　were　included　in　the　safety　analysis.　Results:　The　cure　and　effective　rates　were　39.55%　and　85.07%　in　the　ceftriaxone/sulbactam　group　and　36.43%　and　79.84%　in　the　cefoperazone/sulbactam　group;　the　bacterial　eradication　rates　were　83.58%　and　83.72%;　and　the　adverse-event　rates　were　7.48%　and　7.80%,　respectively.　There　were　no　significant　differences　between　the　two　groups　(p　＞　0.05).　Conclusion:　Ceftriaxone/sulbactam　is　as　effective　and　well-tolerated　as　cefoperazone/sulbactam　for　the　treatment　of　intermediate　and　severe　bacterial　infections　caused　by　resistant　strains.